Sign In
Buy STRO
$23.57
-0.160 (-0.674%)
At Close: Jul 17, 2026
Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript
06:22pm, Wednesday, 12'th Nov 2025
Sutro Biopharma, Inc. ( STRO ) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation November 12, 2025 10:00 AM EST Company Participants Jane Chung - CEO & Dir
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates
07:26pm, Thursday, 06'th Nov 2025
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.59 per share a year ago.
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
04:30pm, Thursday, 06'th Nov 2025
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end –
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
04:05pm, Wednesday, 05'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
08:00am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
05:05pm, Monday, 29'th Sep 2025
– Extends cash runway into at least mid-2027 – SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pion
Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates
06:51pm, Thursday, 07'th Aug 2025
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.59 per share a year ago.
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
04:30pm, Thursday, 07'th Aug 2025
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 –
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
06:56pm, Thursday, 08'th May 2025
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago.
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
04:31pm, Thursday, 08'th May 2025
- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization -
Sutro Biopharma to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 01'st May 2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug c
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
04:05pm, Monday, 28'th Apr 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - - Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - - The late-breaking oral presentati
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
12:09pm, Friday, 14'th Mar 2025
On Thursday, Sutro Biopharma, Inc. STRO prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline.
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates
08:31pm, Thursday, 13'th Mar 2025
Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago.
